

To whom it may concern:

January 6, 2011

RE: FDA's warning letter

We very much regret causing you considerable concern about the FDA's warning letter of December 9, 2010 addressed to us and regarding the inspection made last July.

The letter contains three main particulars on Protamine Sulfate. They mainly refer to specifications and HPLC analytical methods for Protamine Sulfate.

Protamine Sulfate is an API that are proteins extracted from salmon milts, and is composed of several protein subtypes. The FDA's warning letter indicates that, among other things, our analytical method for purity of this product is inadequate. We explained the purpose of our HPLC analysis for Protamine Sulfate during the inspection, and we sent answering letter to FDA in last August.

We have already answered all the FDA's instructions and expect that our responses will be accepted without any problems.

We believe that this case will not affect in any way our other API business in the USA, and we will do our utmost to provide various kinds of high-quality API to satisfy the customer's needs.

We sincerely hope that we can continue our trusted relationship and thank you in advance for your future cooperation.